Key Highlights

  • Compensation includes a $750,000 base salary, eligibility for an annual bonus of up to 90%, and a cash bonus of $337,500 for the calendar year 2026.
  • Equity awards consist of $2 million in common stock options and $12 million in restricted stock units, subject to vesting schedules.
  • Mottiwala will assume the CEO role and board seat in July.

RxSight announced that Aziz Mottiwala will assume the roles of President and Chief Executive Officer, bringing a compensation structure designed to align his interests with the company’s turnaround objectives. The appointment follows a series of leadership transitions that have reshaped the company’s executive team over recent years.

Leadership Shift

Mottiwala enters RxSight after a career focused on building commercial capabilities within the ophthalmic and broader pharmaceutical sectors. Prior to joining RxSight, he held senior commercial positions at Tarsus Pharmaceuticals and Opiant Pharmaceuticals, and spent a decade at a major eye‑care product company where he led marketing and commercial initiatives for its eye‑care portfolio. His experience is aimed at expanding the market reach of RxSight’s Light Adjustable Lens system.

Compensation Structure

The employment agreement provides an annual base salary of $750,000. Mottiwala is eligible for an annual bonus that can reach up to 90% of his base salary, and a cash bonus for the calendar year 2026 equal to $337,500. The equity component is valued at $14,000,000 on the date of grant and is divided between two elements:

Common Stock Options, worth $2,000,000, with 25% vesting after the first anniversary of the grant date and the remaining portion vesting monthly over the subsequent three years. Restricted Stock Units (RSUs), worth $12,000,000, vesting on a schedule of 20% at the one‑year anniversary, an additional 20% after the second year, and the remaining 60% after the third year. Both the options and the RSUs are contingent on continued service and will accelerate to full vesting if a change‑in‑control event occurs, representing a 100% acceleration provision.

Strategic Implications

The Light Adjustable Lens is the only FDA‑cleared intraocular lens that can be fine‑tuned after cataract surgery, offering a differentiated solution in a competitive marketplace. By appointing a leader with a strong commercial track record, RxSight signals a strategic emphasis on market adoption and revenue growth rather than solely on product development. The structured equity awards are intended to motivate long‑term performance that is directly linked to shareholder value.

Outlook

Mottiwala is set to begin his tenure in July, at which point investors and analysts will look for early indications of a revised commercial strategy, including potential collaborations, pricing initiatives, and market expansion efforts. The company has not revised its financial outlook in conjunction with the announcement, making upcoming earnings releases the primary venue for assessing the impact of the leadership change. All information is based on the Form 8‑K filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.